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ABSTRACT 
Background: Attention Deficit/Hyperactivity Disorder (ADHD) is overrepresented in prison, making 
it imperative to identify a screening tool that can be quickly applied to efficiently detect the disorder. 
We explored the discrimination ability of a widely used ADHD screen, the Barkley Adult ADHD 
Rating Scale (BAARS-IV), against a clinical diagnostic interview. A brief version of the screen was 
then developed in order to simplify its use in the prison context, and maximise its diagnostic 
properties. Methods: A cross-sectional study of 390 male prison inmates performed in the United 
Kingdom, who were all screened and interviewed via the Diagnostic Interview for ADHD in Adults 
2.0 (DIVA-2). Results: A total of 47 (12.1%) inmates screened positive for ADHD using the full 
BAARS-IV, and 96 were clinically diagnosed (24.6%), for a sensitivity of 37.9 and specificity of 
96.3. Our models identified the six items that most predicted ADHD diagnosis, with adjusted Odds 
Ratios (OR) ranging from 2.66 to 4.58. Sensitivity, specificity and accuracy were 0.82, 0.84 and 0.84 
for the developed brief scale, and 0.71, 0.85 and 0.81 for its validation, with weighted probability 
scores producing AUC of 0.89 and 0.82, respectively. Conclusions: The original BAARS-IV 
performed poorly at identifying prison inmates with ADHD.  Our developed brief scale substantially 
improved diagnostic accuracy. The brief screening instrument has great potential to be used as an 
accurate and resource effective tool to screen young people and adults for likely ADHD in the 
criminal justice system.  
Keywords: ADHD, diagnosis, prison, screening, criminal justice system 
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INTRODUCTION 
Attention Deficit/Hyperactivity Disorder (ADHD) in adults is a highly prevalent mental 
health disorder in the USA (4.4%)(Kessler et al., 2006) and worldwide (2.8%-5.3%)(Polanczyk et al., 
2007, Simon et al., 2009). Clinically significant symptoms of inattentiveness, hyperactivity and 
impulsivity usually start in childhood (American Psychiatric Association, 2013). ADHD is also 
associated with problems related to executive functioning, including the ability to self-regulate 
(Velez-Pastrana et al., 2015). Approximately 65% of those diagnosed in childhood persist in the 
disorder into adulthood (Faraone et al., 2006). Long-term adverse outcomes for ADHD have been 
documented in a wide range of areas, including school and occupational performance (Shaw et al., 
2012), interpersonal relationships (Moya et al., 2014) and comorbidity, including conduct disorder, 
antisocial personality, and substance use (Levin et al., 2004, van Emmerik-van Oortmerssen et al., 
2012). Its burden of disease is evidenced by an increased likelihood for serious accidents (Barkley et 
al., 1993, Chang et al., 2014), earlier mortality rates (Dalsgaard et al., 2015), delinquency and 
criminality (Gonzalez et al., 2013, Young et al., 2014). 
Considerable evidence supports an over-representation of youths and adults with ADHD in 
correctional services. Meta-analytic prevalence estimates reported from 42 prison studies indicate 
that 30% of adults in prison were classified as ADHD cases (Young et al., 2014). ADHD is 
increasingly recognised as a significant factor in prisoners’ health; studies amongst prison inmates 
with ADHD have found them at risk of increased psychiatric comorbidity and poorer psychosocial 
adjustment to the prison environment (Gonzalez et al., 2015, Gudjonsson et al., 2009, Young et al., 
2015, Young et al., 2011b). Yet despite this high prevalence amongst inmates, ADHD is rarely 
diagnosed and treated by offender mental health teams (Young et al., 2011a). This may be explained 
by the exclusion of ADHD in routine prison screening protocols in the criminal justice system.  
Unless healthcare screens include the condition, there is a risk that ADHD will be missed or 
misdiagnosed and, in turn, individuals with ADHD in the criminal justice system will not receive 
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appropriate treatment and support. Given the evidence that interventions are effective in this 
population at both individual (Ginsberg et al., 2012) and a wider population level (Lichtenstein et al., 
2012), it is imperative that these individuals are identified.  
As a neurodevelopmental disorder, the diagnostic process for ADHD in adulthood is 
complicated by the necessity to determine whether symptoms were present in childhood, thereby 
often relying on retrospective recall that is usually self-reported.  Moreover, the diagnostic criteria 
include a wide range of symptoms that may overlap with other mental health disorders. For instance, 
attentional symptoms are present in anxiety, depression and substance use disorders, and impulsivity 
is present in bipolar disorder and borderline and antisocial personality disorders (American 
Psychiatric Association, 2013). ADHD is also highly comorbid with other disorders and it is not 
uncommon for co-existing affective and anxiety disorders to be the reason for seeking and receiving 
services.  
Screening tools are most commonly applied to indicate the likelihood of a subsequent ADHD 
diagnosis upon further clinical evaluation.  They can provide a cost-effective way to identify 
individuals with sufficient ADHD symptoms to warrant a comprehensive psychiatric diagnostic 
interview, which includes an assessment of the presence of symptoms, their onset, associated 
impairment, differential diagnosis and/or comorbidity.  However there are various problems with 
existing rating scales, many of which have simply mirror the diagnostic criteria and so add 
considerably to the duration of an already lengthy prison healthcare screen.  The briefest screening 
tool available is the 6-item Adult Self- Report Scale (ASRS)(Kessler et al., 2005, Kessler et al., 
2007).  This has been frequently used for community epidemiological research as it has strong 
concordance with clinical diagnoses, with a reported area under the curve (AUC) of 0.90. A major 
drawback with the brief ASRS is that it solely provides information on current symptoms, requiring 
researchers to administer a different measure for retrospective assessment (Daigre et al., 2015, 
Ginsberg et al., 2012), such as the Wender Utah Rating Scale (Ward et al., 1993). Furthermore, 
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screening tools might differ in their predictive validity amongst different patient samples. Alternative 
cut-off scores have been reported for the ASRS depending on the population, for example for 
screening ADHD among alcohol dependent patients (Daigre et al., 2015) and for substance 
dependent patients seeking-treatment (van Emmerik-van Oortmerssen et al., 2012).   
Given the very high rates of ADHD in prison samples, it is a priority to identify a screening 
tool that can be quickly and easily applied, and that accurately predicts the presence or absence of 
the disorder.  A meta-analysis of rates of ADHD reported in youth and adult prisoners found that 
rates based on a screening methodology were significantly higher than when rates were obtained 
using a clinical diagnostic interview (43.3% v. 25.5% respectively)(Young et al., 2014).  This 
suggests that the current screening process in this population is identifying a high false positive rate. 
The development of a screen that is more concise yet accurate in predicting presence or absence of 
an ADHD diagnosis would be advantageous within the justice system.   
This study therefore aimed to address these limitations by developing an empirically derived 
ADHD screen tested against a clinical diagnostic interview in a large sample of male adult offenders.  
First, we explored the discriminative ability of a widely used ADHD screen, the Barkley Adult 
ADHD Rating Scale (BAARS-IV)(Barkley, 2011) against a clinical diagnostic interview that is in 
international use, the Diagnostic Interview for ADHD in Adults (DIVA-2)(Kooij, 2010). Second, we 
developed a brief version of the screen in order to simplify its use for greater efficiency and cost-
effectiveness while maximising its psychometric properties. Third, we provide internal validation 
and cross-validation on our derived brief scale.  
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METHODS 
Participants  
Participants were 392 males who were either serving sentences or were on remand at HMP 
Inverness (Porterfield).  Two cases were excluded from analysis for missing essential information in 
the ADHD diagnostic interview. Table 1 presents demographic data, ADHD screening results and 
clinical diagnosis frequencies.  
Instruments 
 BAARS-IV 
The BAARS-IV is an empirically developed self-rating scale, based on DSM diagnostic 
criteria, that evaluates the most reliable underlying dimensions of the symptom list for adults 18-81 
years(Barkley, 2011). The BAARS-IV assesses the 18 current and 18 childhood symptoms of ADHD 
along with age of onset and several domains of impairment, with reported alphas of 0.92 and 0.95, 
respectively. To simplify the use of the BAARS-IV as a screening instrument, ordinal scale items (0-
4) were recorded into presence/absence of symptoms (0, 1) provided the item was answered as 3 or 4 
(often or very often). For the present study and consistent with DSM-5 criteria, a symptom count of 
six or more for I/A or H/I lists were required for retrospective childhood self-report, and five or more 
in the last six months for current self-report. 
Structured Diagnostic Interview 
All participants were interviewed using the DIVA(Kooij, 2010), regardless of their previous 
ADHD BAARS-IV screening results. The DIVA is a validated structured interview for ADHD in 
adulthood that allows assessing symptoms retrospectively as well as currently. The DIVA is divided 
into categories of inattention (I/A), hyperactivity/impulsivity (H/I) and a section for impairment. For 
each of these areas, questions address current symptom presentation, and those present as a child 
(ages 5 to 12). Akin to the gold standard in clinical practice - the CAADID - the DIVA uses the 
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symptoms of ADHD as described in DSM-IV. Adaptation to the current DSM-5 only required 
changing the age of symptom onset criterion. Participants are subsequently asked if problems with 
I/A and H/I have interfered with five different areas of their lives: work or education, relationships 
and family, social contacts, free time and hobbies and self-confidence/self-image. The DIVA-2 is 
very frequently used, particularly in Europe, and has been recently employed in clinical settings 
(Deberdt et al., 2015), amongst older adults (Semeijn et al., 2015), and in police custody (Young et 
al., 2013). The DIVA-2 has also been used as the criterion for validation of an ADHD screening tool 
for older adults (Semeijn et al., 2013).   
When applying DSM-5 criteria, six or more symptoms of I/A or H/I are required to have been 
present often in childhood, by the age of 12 years; for older adolescents and adults (age 17 and older) 
at least five symptoms on either dimension must be present.  In addition symptoms must have 
persisted for at least six months, to a degree that is inconsistent with developmental level, and that 
negatively impacts social and academic/occupational activities.  Subgroup classifications can be 
made for those meeting only I/A criteria (predominantly inattentive presentation), those meeting only 
H/I criteria (predominantly hyperactive/impulsive presentation) or combined presentation for those 
meeting both I/A and H/I criteria. 
We also recorded cases that did not meet the impairment or the age of onset criteria (i.e., 
ADHD NOS). Specifically, age of symptom onset was set at < 18 for the ADHD NOS group. 
Diagnosis history  
A question addressed whether a doctor or mental health professional had ever diagnosed 
participants with ADHD. Two additional questions queried whether they had received medication 
treatment for ADHD, or for a general psychiatric illness.  
Procedures 
Following approval from the Scottish Prison Service (reference: 7/13/10/10), an all male 
sample was recruited by opportunity sampling from Porterfield Inverness Prison (UK) over a period 
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of 18 months. Participants were informed about the study by flyers placed on noticeboards by a 
member of the prison staff, and from individual letters. Those who indicated interest attended an 
appointment with the researcher when they were given detailed written information about the study 
and the consent procedures. The researcher ensured that all participants understood the information 
handed to them and answered questions. The information and consent sheets were read out to 
participants of poor literacy. Participants were informed that their participation was voluntary and of 
their right to withdraw at any time. After providing informed consent, participants met with the 
researcher in an individual booth within an area of the prison dedicated to support therapeutic 
services.  A comprehensive battery of measures was administered, taking approximately 4 hours in 
total, and the vast majority of participants took up the option to split data collection across 2 or 3 
sessions (depending on fatigue and ability).  The battery of assessments included the two measures 
reported in the present study: the BAARS-IV and the DIVA-2 diagnostic interview. Two researchers 
had previously attended individual and comprehensive training sessions at the Maudsley Hospital 
Adult ADHD Service to administer these measures, which included watching and scoring video 
recordings of patients attending that service to ensure reliability.  £20 was paid into the Prison 
Common Good Fund for the participation of each prisoner. This fund is managed by a group of 
prisoners and the funds can be used to purchase items for the common good of all prisoners and 
enhancing prison life.  
Analytical strategy 
Scores from the BAARS-IV were dichotomised into “ADHD” or “no ADHD” depending on 
whether they exceeded the symptom count thresholds from the manual. Similarly, DIVA 
assessments were made binary into “ADHD” and “no ADHD” based on their classification, 
including categories of predominantly inattentive, predominantly impulsive and combined into the 
“ADHD” group. Using the DIVA derived diagnosis as the reference, sensitivity, specificity, positive 
predictive value (PPV) and negative predictive value (NPV) of different cut-offs were calculated. 
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The cut-off scores for the BAARS-IV child symptoms and adult symptoms were the ones that 
optimized all of the above-mentioned parameters. The Area under the ROC Curve (AUC) was used 
as the statistical measure to compare the final diagnostic models of the screening instruments. An 
increase in AUC represents higher specificity (i.e., correctly identification of non-cases) for each 
level of sensitivity (i.e., cases correctly identified). Therefore, a higher AUC represents better 
screening and diagnostic performance (Singh, 2013). 
After examining the original full BAARS-IV predictive accuracy, we developed the brief 
screening tool from the best subset of its items in this prison sample. In order to select the best and 
most predictive items, we first randomly split the sample by half (50:50). For the screen development, 
the ADHD DIVA diagnosis was regressed on all BAARS-IV items using logistic regression with 
stepwise selection of significant predictors. We then created a symptom additive scale to derive a 
simple cut-off score for practical use, and obtained the above-mentioned parameters to select the 
optimal value. Furthermore, a more precise form of the screen was obtained by calculating each item 
weighted based on their regression coefficients from the model. This weighted probability score was 
used to derive the AUC of our screening tool and Receiver Operating Characteristics (ROC) curve. 
For the brief screening tool we identified the optimal cut-off point based on having an 
acceptable level in the internal validation sample (50%) for the trade-off between sensitivity and 
specificity. This selection was aided by using the Youden’s Index (Schisterman et al., 2005)  J = 
([sensitivity + specificity] – 1). The Youden’s index places equal importance on values of sensitivity 
and specificity, therefore on false positive and false negative cases. In addition to these statistical 
measures of screening performance, we also report PPV, NPV and percentage correctly classified 
(i.e., % accuracy) for the brief scale.  
For validation, the selected items additive scale and the weighted probability scores were 
tested in the other half-sample. To provide further evidence for validation of the brief diagnostic tool, 
we used Leave One Out cross-validation (LOOCV), a form of resampling type of cross-validation. 
 10 
LOOCV allows employing the total sample as a new sample by combining the results using the 
sample n times, each time with one observation left out (n-1)(Bautista et al., 1999).  The parameter 
estimates in each n-1 sample are used to generate predicted values only for the one left-out 
observation. Both the internal validation and cross-validation (LOOCV) procedures were repeated on 
cases classified as ADHD NOS. The latter analysis will allow estimating how our prediction models 
fare in cases that are likely to present clinically significant symptoms, which may also require 
treatment, but fail to meet standard criteria based on age of onset. Thus, this will provide further 
ecological validation of the screening instrument. All analyses were performed using Stata 13 
(Statacorp, 2013). 
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RESULTS 
Demographics, screening and diagnosis prevalence of ADHD 
The sample was essentially white British (99.0%).  The average age was ?̅? = 30.3, with the 
ADHD group having significantly lower mean age (?̅? =28.2, s.d. = 7.5) than those without ADHD 
(?̅? =31.0, s.d. = 8.5; t (df) = -2.91 (388), p < 0.01). Effect size for this age contrast was moderate at 
0.343 (CI 95% 0.111, 0.574).  
Only eighteen participants (18.8%) out of 96 who were diagnosed with ADHD in the present 
study reported having been diagnosed with the disorder prior to the study, and 15 (15.6%) reported 
having received pharmacological treatment for ADHD. About half (53.1%) of those diagnosed with 
ADHD in the study reported having taken general psychiatric medication. 
____________________________ 
Insert Table 1 about here 
____________________________ 
 
Using the BAARS-IV, the retrospective scale produced 151 (38.8%) of the total sample that 
screened positive for likely having ADHD in childhood.  For current symptoms, 70 (18.0%) were so 
classified.  The prevalence rate was 12.1% as 47 inmates screened positive for both childhood and 
current symptoms. The data, including classification frequencies by ADHD subtypes, are included in 
Table 1.  
Using the DIVA-2, both the retrospective symptom and the current symptom count (based on 
interview) produced the same result, with 177 (45.4%) of the total sample surpassing the symptom 
cutoffs, respectively. The prevalence rate was 31.8% as 124 inmates met symptom criteria for both 
childhood and current symptoms.  We next applied the impairment (i.e. impairment in two or more 
areas) and age of onset criteria. Whilst DSM-5 criteria requires onset by age 12, we also included 
those participants reporting onset at age 12 due to the unreliability of retrospective recall of symptom 
onset(Barkley et al., 2008) and the high frequency of this value and sharp decline thereafter. After 
excluding seven participants from the classified group for having an age of symptom onset after 12 
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years, 15 participants for not meeting the impairment criterion, and 6 that failed to meet both, the 
ADHD group consisted of 96 individuals.  This yielded a lower prevalence of 24.6%. To provide 
further validity on our derived brief screening tool, we estimated its diagnostic utility on the DIVA 
classified cases that did not meet the impairment or the age of onset criteria. Specifically, age of 
symptom onset was set at < 18 for this ADHD not otherwise specified (NOS) group.  
Diagnostic accuracy of the BAARS-IV screen 
The BAARS-IV original scale had sensitivity, specificity, PPV, NPV and total percentage of 
correctly classified as 37.9, 96.3, 76.6, 82.8 and 82.0 respectively. In clinical terms this is not 
adequate, due to the high number of false positives. To address this, we examined the diagnostic 
accuracy of the symptom scales by fitting the total symptoms of childhood and current symptoms 
independently. Figure 1 includes these results for each of the 18-symptom scales with optimised cut-
off scores. Clinically, 9 out of 18 items warrant diagnosis, but the optimised cut-off value for the 
childhood BAARS-IV symptom scale was ≥ 11, whereas for the current BAARS-IV symptom scale 
this was only ≥ 4. Both symptoms scales notably improve on the sensitivity indices compared with 
the full BAARS-IV classification, but lose specificity and accuracy.  
____________________________ 
Insert Figure 1 about here 
____________________________ 
 
Development and diagnostic accuracy of the BAARS-IV brief screen 
The ADHD DIVA diagnosis was regressed on all BAARS-IV items using logistic regression 
with stepwise selection of significant predictors. The final model produced a solution with six items, 
three from childhood and three from adulthood, which had significant risk associations with the 
diagnostic interview results, with Odds Ratios (OR) ranging from 2.66 to 4.58. The specific items, 
beta coefficients and confidence intervals (95%) are all included in Table 2. The single item that was 
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most predictive of ADHD classification was (children retrospective scale 18) Interrupted or 
intruded on others, based on an AUC of 0.78 (sensitivity 67.7%, specificity 81.3%, accuracy 78.0%). 
_______________________________ 
Insert Table 2 and Table 3 about here 
_______________________________ 
 
Scoring each item on a simple yes/no basis provides an additive scale ranging from 0 to 6. 
Splitting the sample randomly in half to give a ‘development’ and a ‘validation’ sample, and using 
the Youden’s J index indicates that in both samples a cut-off of ≥ 3 gives optimal performance (see 
Table 3). Using a more complex scoring system for each item, namely calculating the weighted 
probability, based on each item’s regression coefficient, and then plotting the ROC curve (see Figure 
2) for development split-half (50%), validation split-half (50%), and Leave one out cross-validation, 
reveal AUC’s of 0.89, 0.81 and 0.82 respectively. 
____________________________ 
Insert Figure 2 about here 
____________________________ 
 
Finally, we explored the diagnostic utility of our derived brief BAARS-IV scale on cases 
classified as ADHD NOS. The internal validation (50%) and cross-validation (LOOCV) methods 
both produced AUC values of 0.78.   
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DISCUSSION 
In this study we set out to evaluate the BAARS-IV(Barkley, 2011) as a diagnostic screening 
measure for detecting ADHD cases in a UK prison sample.  We did so utilising a valid and 
frequently used clinical interview for diagnosis. We then proceed to develop a briefer scale that 
maximised diagnostic accuracy and efficiency. To our knowledge, this is the first study to examine 
both false positive and false negative rates when screening for ADHD in a prison sample. High rates 
for both were found. The original BAARS-IV performed poorly at identifying prison inmates with 
ADHD (0.38), but had high ability to identify non-cases (0.96) and an overall AUC of 0.67.  
However the briefer scale substantially improved the diagnostic parameters of sensitivity (84.0), 
accuracy (83.6) and overall AUC (0.89), with robust specificity (82.2). Internal validation (AUC 
0.81) and cross-validation (AUC 0.82) findings confirmed its potential usefulness to screen for 
ADHD in different samples of prison inmates.  Screening for ADHD NOS cases was satisfactory in 
this sample, which provides further evidence of diagnostic validity.  
A clear strength of the brief diagnostic screening tool is that it includes both childhood and 
current ADHD indicators. Our modelling approach allowed examination of the potential contribution 
of all 36 items and produced a solution that equally represented childhood and current symptoms (i.e. 
three items in each). In the context of clinical practice, this finding is consistent with the chronic 
nature of ADHD symptom domains of I/A and H/I. Childhood symptoms on the brief screen were 
seemingly more predictive of ADHD status than adult symptoms, when contrasting their individual 
diagnostic screening capacities using total number of symptoms. The symptom average was higher 
in childhood than in current self-reports of prisoners, and the screened prevalence was also higher 
retrospectively (39.8% v. 17.9%), which is consistent with symptom decline with age (Faraone et al., 
2006). 
The three childhood items empirically selected by our model all queried ADHD indicators 
that are relevant to the domain of school and school performance, and one specifically referred to 
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behaviour in the classroom. One of these items was the single most predictive item of the BAARS-
IV, Interrupted or intruded on others. School problems, including behavioural and academic 
difficulties, and resultant school drop-out are all established risk factors for delinquency and 
incarceration (Murray and Farrington, 2010). School-based detection of ADHD symptoms of 
inattention, hyperactivity and impulsivity can be explored in combination with other known risk 
factors for delinquency and imprisonment such as conduct problems (Koegl et al., 2009), peer 
antisocial activity (Loeber and Farrington, 2000) and history of bullying or having being bullied 
(Farrington et al., 2011, Ttofi and Farrington, 2012). For instance, in our sample, only 18.8% of 
individuals who were diagnosed in this study with ADHD had been previously detected by a 
physician or mental health professional, and only 15.6% had received targeted pharmacological 
treatment for their symptoms.  This is consistent with earlier community-wide studies such as the 
National Comorbidity Survey (Kessler et al., 2006) that found only 10% of adults with ADHD had 
ever been diagnosed with it previously.  Such results emphasise that ADHD is being substantially 
missed in at-risk individuals or being misdiagnosed.  Early detection of cases affords the opportunity 
for early intervention and interruption to the antisocial trajectory (Lichtenstein et al., 2012).  
Notwithstanding the age of onset criterion having been recently modified to include those 
with onset up to 12 years, we also included those who reported onset of symptoms at 12 years. 
Notably, the frequency for onset at age 12 was remarkably high, and followed an upward trend from 
all previous age categories, whereas onset on and after age 13 sharply declined. Requesting 
individuals to think and recall back to this time may be difficult and they may find it easier to 
distinguish between the move from junior and senior school around this age.  
The BAARS-IV full scale based on the DSM algorithm performed poorly in terms of 
detection of cases, and also produced a much lower prevalence rate than expected (12.1%). 
Nevertheless, this is consistent with our previous prison study using a DSM-IV based rating-scale 
that assessed symptoms retrospectively and currently, producing a screening rate of 14%(Young et 
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al., 2009). This may suggest that at least in prison inmates, assessing full standard criteria as self-
report of symptoms are not advised.  
A key strength of the study is its large sample size and a methodology in which every 
participant in the sample was screened and interviewed using the DIVA-2 – a diagnostic clinical 
interview of ADHD in international use.  This methodology allowed us to investigate both false 
positive and false negative rates in this population for the first time. Findings are thus generalizable 
to other male offender populations.  This is exemplified by the ADHD prevalence rate of 24.6% 
obtained in the present study, which is remarkably consisted with a recent meta-analytic rate based 
on 42 studies at 26-30% (Young et al., 2014). However, our sample was restricted to males and that 
is a limitation. Future research should extend this protocol to female offenders with ADHD who may 
present as clinically distinct from community females with ADHD, in terms of comorbidity, severity 
and impairment (Gonzalez et al., 2015, Konstenius et al., 2015, Young et al., 2014). We performed 
internal validation and provided confirmation by using LOOCV cross-validation. Because 
performance on the LOOCV model was similar to the half-sample trial it may be expected that the 
test performance in another sample would be equally adequate. Nevertheless, administering the 
screening tool in an entirely new sample would represent an ideal validation group, which was not 
available for the present study. Therefore, a next step in validation is to perform the protocol in an 
external, independent sample of offenders. Our objective was to generate and to provide the first line 
of validation for a screening tool that would be particularly suited for ADHD in a criminal justice 
sample. Replication studies should provide definitive proof of its diagnostic qualities further in 
subsequent studies. We also advice examining the brief screen’s external validity as applied in 
clinical settings.  
 The findings are clear that this brief screening tool has considerable promise as an accurate 
and resource effective tool to adult males in the criminal justice system who are likely to have 
ADHD.  It also has the potential to be of value in other populations, both clinical and 
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educational/occupational, and future research should aim to establish the utility of the screen more 
widely.  
The proportion of inmates in prisons is increasing worldwide (Walmsley, 2013), but 
particularly in the US is estimated at more than 1%
 
(Pew Charitable Trusts, 2008).  Many of these 
inmates will likely meet diagnostic criteria for ADHD
 
(Young et al., 2014), and in turn will be 
released from prison and will require community mental health services. Efficient identification in 
prison may lead to adequate interventions that could prevent adverse functional outcomes for the 
individual and for society.  
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Table 1. Screening rates and prevalence of BAARS-IV and DIVA-2 (n = 390) 
 BAARS      DIVA-2     
 None I/A H/I Combined Total 
Classified 
 None I/A H/I Combined Total 
Classified 
Childhood, N
o
 239 45 25 81 151   213 53 39 85 177  
  % 61.2 11.6 6.4 20.8 38.8  54.6 13.6 10.0 21.8 45.4 
Current, N
o
 320 21 24 25 70  213 56 51 70 177  
  % 82.1 5.4 6.2 6.4 18.0  54.6 14.4 13.1 18.0 45.4 
ADHD classified 
N (%) 
    47 (12.1)      124 (31.8) 
  Age of onset > 17
a
     -      4 (3.2) 
  ADHD NOS     -      120 (30.8) 
  Age of onset > 12
a
     -      13 (10.5) 
  No impairment 
criterion
a, b 
 
    -      21 (16.9) 
  ADHD DSMV     -      96 (24.6) 
Note: BAARS - Barkley Adult ADHD Rating Scale, DIVA – Diagnostic Interview ADHD, NOS – Not otherwise specified, I/A – Inattention, H/I – 
Hyperactivity/Impulsivity. 
a
Percentage out of those classified by DIVA 
b6 cases did not meet age of onset ≤ 12 nor the impairment criterion. 
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Table 2. Logistic regression model results for child and current BAARS-IV items directly 
associated with DIVA interview-derived ADHD diagnosis (n = 195)  
BAARS items B Std. error OR 95% CI 
Childhood     
4. Left seat in classroom and other situations 
in which seating was expected 
1.16 0.55 3.18 1.08, 9.40 
13. Lost things necessary for tasks and 
activities 
0.98 0.48 2.66 1.04, 6.82 
18. Interrupted or intruded on others 1.52 0.51 4.58 1.68, 12.52 
Current      
2. Fidgets with hands or feet or squirm in seat 1.01 0.48 2.74 1.07, 7.03 
8. Have difficulty engaging in leisure 
activities or doing fun things quietly 
1.35 0.65 3.85 1.09, 13.65 
16. Have difficulty waiting turn 1.32 0.50 3.75 1.40, 9.99 
Note: Items selected previously from stepwise model, forward selection from the pool of all 
BAARS items 
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Table 3. Diagnostic accuracy of the Brief BAARS 
     
Cut-off values Sensitivity Specificity % Accuracy  Youden’s J 
Development     
≥ 1 0.933 0.420 53.9 0.353 
≥ 2 0.933 0.660 72.3 0.593 
≥ 3 0.822 0.840 83.6 0.662 
≥ 4 0.556 0.953 86.2 0.509 
≥ 5 0.311 0.993 83.6 0.304 
≥ 6 0.222 0.100 82.1 -0.678 
     
Validation (50% Split-half)    
≥ 1 0.902 0.396 0.528 0.298 
≥ 2 0.843 0.646 0.697 0.489 
≥ 3 0.706 0.847 0.810 0.553 
≥ 4 0.392 0.965 0.815 0.357 
≥ 5 0.137 0.986 0.764 0.123 
≥ 6 0.078 0.993 0.754 0.071 
Note: Development AUC 0.885 (CI 95% 0.823, 0.947) n = 195; Validation AUC 
0.822 (CI 95% 0.750, 0.894) n = 195 
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